Did Trump Give Roundup Legal Immunity? What the 2026 Glyphosate Order Actually Changed

No. President Donald Trump’s February 2026 executive order did not give Roundup manufacturers blanket immunity from cancer lawsuits. It invoked a federal law that protects certain actions taken to comply with government production directives. Separately, the Supreme Court restricted lawsuits that would require cancer warnings different from those approved by the Environmental Protection Agency (EPA). Neither development established that Roundup cannot cause cancer, and neither automatically eliminated every possible product-liability claim.

The distinctions became clearer on October 1, 2026, when a federal judge allowed two Roundup claims to proceed despite the Supreme Court’s June ruling. Meanwhile, EPA and the Department of Health and Human Services (HHS) are conducting a renewed scientific review of glyphosate, the active ingredient in many Roundup formulations.

Four separate processes are involved:

The practical question is not whether Roundup received some legal protection. It did. The question is which activity is protected, under which law, and against which kind of claim.

What Trump’s Glyphosate Executive Order Actually Does

On February 18, 2026, Trump signed Executive Order 14387, Promoting the National Defense by Ensuring an Adequate Supply of Elemental Phosphorus and Glyphosate-Based Herbicides.

The order treats domestic production of two related materials as a national-security concern:

• Elemental phosphorus, used in military and industrial supply chains, including some defense-related applications.
• Glyphosate-based herbicides, which depend on phosphorus chemistry and are widely used to control weeds in American agriculture.

The order’s rationale combines military supply security with food-supply security. The White House argues that an interruption to domestic production could increase dependence on imports and threaten agricultural productivity. It also states that the United States has only one domestic producer of both inputs and imports more than 6 million kilograms of elemental phosphorus annually. Those are administration findings, not independently established production increases resulting from the order.

The powers given to USDA

Section 2 delegates authority under Section 101 of the Defense Production Act to the secretary of agriculture. That authority can be used to prioritize contracts and orders, and to allocate materials, services, and facilities for national-defense needs. The executive order directs USDA to determine necessary priorities and allocations in consultation with defense officials and to issue implementing orders or regulations as necessary.

This does not mean a factory automatically receives a purchase order, subsidy, or instruction to produce a particular quantity of glyphosate. Those outcomes would require separate implementation evidence.

The order references 7 C.F.R. Part 789, the Agriculture Priorities and Allocations System, which contains the procedures for rated orders, allocations, compliance, and appeals.

The provision about a producer’s financial viability

Section 2(d) is especially notable. It directs the secretary to ensure that an implementing order, rule, or regulation does not put the corporate viability of a domestic producer at risk.

That is a concrete policy instruction concerning the financial consequences of federal production measures. It is not, by itself, a grant of money, a court ruling, or proof that a company’s finances improved.

Bayer said in July 2026 that it had consolidated its U.S. glyphosate operations into Ruveon, a distinct business within the Bayer Group. The reorganization is relevant to identifying companies in the domestic supply chain. But its timing alone does not establish that the executive order caused the restructuring.

What remains unverified: In the public records examined for this article, we could not establish a specific USDA-rated glyphosate production order, a resulting increase in domestic output, or the financial effect of implementing directives on a particular manufacturer. The authority exists; its measurable implementation is a separate question.

Did the Order Give Glyphosate Manufacturers Immunity?

It invoked an existing statutory protection, rather than creating unlimited immunity by presidential declaration.

Section 3 of the executive order expressly invokes Section 707 of the Defense Production Act, codified at 50 U.S.C. § 4557. The statute protects a person from damages or penalties for an act or failure to act resulting directly or indirectly from compliance with a qualifying Defense Production Act rule, regulation, or order, even if the underlying directive is later declared invalid.

The decisive words concern conduct resulting from compliance.

Consider two hypothetical situations:

1. A federal priority order requires a manufacturer to fulfill an urgent government-directed supply obligation first. The manufacturer consequently misses a conflicting commercial delivery deadline. Section 707 may protect conduct attributable to compliance with that directive.
2. A consumer alleges that an herbicide formulation manufactured years earlier was defectively designed and caused cancer. Merely selling a product whose supply is now considered strategically important does not automatically prove that the alleged defect resulted from compliance with a federal production order.

These are illustrations, not predictions about a particular lawsuit. A court would need to examine the actual federal instruction, the challenged conduct, causation, jurisdiction, and other applicable law.

What the Agent Orange cases say

The most useful historical evidence comes from litigation involving Agent Orange, the defoliant manufactured for the U.S. military during the Vietnam War. The chemical and its exposure history are different from Roundup’s, but the disputes involved the same Defense Production Act immunity provision.

In Hercules Inc. v. United States (1994), the Federal Circuit addressed manufacturers’ efforts to shift Agent Orange litigation costs to the government. It reasoned that Section 707’s protection relates to the risks imposed by federal priority requirements, rather than automatically covering the risk that a government-ordered product is inherently unsafe.

In United States v. Vertac Chemical Corp. (1995), the Eighth Circuit applied related reasoning and rejected the argument that Section 707 automatically shielded an Agent Orange manufacturer from environmental cleanup liability under CERCLA.

Neither case is a ruling about Roundup. Together, however, they offer a legal distinction that matters directly to claims of blanket immunity: a requirement to prioritize production is not necessarily a government instruction to make a harmful product design.

A 2026 pipeline case tested the protection again

A more recent decision shows why the statutory question cannot be reduced to a simple claim that Section 707 applies only to broken contracts.

On August 19, 2026, in litigation concerning Sable Offshore’s California pipeline, a federal district court examined the effect of an actual Defense Production Act allocation order. The court concluded that California could not use a state trespass action to prevent pipeline operations that the federal order compelled. At the same time, it imposed a $1.449 million penalty for a separate violation of an existing federal consent decree.

The court discussed Hercules and Vertac and distinguished activity directly compelled by an allocation order from allegations that a chemical product was dangerous because of its design.

The evidence-supported conclusion: Section 707 is a real and potentially important defense. Its language is broad, and courts have treated compelled compliance seriously. But the precedents do not establish that the February glyphosate order erases liability for all earlier Roundup products or all alleged cancer injuries. We identified no reported ruling through October 16, 2026, applying that executive order’s Section 707 language to dispose of an individual Roundup cancer claim.

What the Supreme Court Changed in Monsanto v. Durnell

The other major legal protection arrived through a completely different statute.

On June 25, 2026, the Supreme Court ruled 7-2 in Monsanto Co. v. Durnell. The case concerned the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which governs pesticide registration and labeling.

John Durnell alleged that long-term Roundup exposure caused his non-Hodgkin lymphoma. A Missouri jury had awarded him $1.25 million on a failure-to-warn claim. The legal question before the Supreme Court was whether state law could impose that warning obligation when EPA had approved Roundup labeling without a cancer warning.

Writing for the majority, Justice Brett Kavanaugh concluded that FIFRA’s express preemption provision bars the state-law claim at issue because it would require a warning in addition to or different from federal labeling requirements. Justices Ketanji Brown Jackson and Neil Gorsuch dissented, taking a different view of the relationship between the federal labeling regime and state-law claims.

The ruling decided a labeling question, not a biological one. It did not conduct an independent clinical or epidemiological investigation to determine whether Roundup causes cancer.

That distinction matters because a manufacturer’s legal duty to use an EPA-approved label and the scientific accuracy of a pesticide risk assessment are separate questions. A later EPA reassessment could change regulatory obligations without altering what the Supreme Court held about the legal framework in Durnell.

Can People Still Sue Monsanto Over Roundup?

Some claims can still proceed, depending on their legal basis and the facts. The clearest example after Durnell is the October 1, 2026, decision in Hoge v. Monsanto Company.

Merril Hoge alleged that Roundup exposure caused his non-Hodgkin lymphoma. Monsanto sought summary judgment following the Supreme Court ruling, arguing that the decision foreclosed his remaining theories. The Idaho federal court reached a more limited conclusion:

• Failure to warn: Dismissed on the evidence and legal theory presented in that case.
• Negligence: Allowed to proceed insofar as it rested on conduct independent of the federally approved label.
• Design defect: Allowed to proceed because material factual disputes remained.

The court cautioned that plaintiffs cannot merely rename a preempted labeling claim as negligence or design defect. The substance of the claim still matters.

The surviving claims were not findings that Monsanto caused Hoge’s cancer. Summary judgment asks whether sufficient factual disputes exist to require a trial, not which side ultimately wins. The court had reset trial for February 2027.

Someone considering litigation cannot assume that every Roundup claim remains available. The controlling jurisdiction, product, exposure history, claimed injury, available evidence, statutes of limitations, and any settlement release can materially affect the answer.

What About the Proposed $7.25 Billion Roundup Settlement?

On February 17, 2026, one day before the executive order, Monsanto announced a proposed nationwide class settlement of up to $7.25 billion. The timing is established; coordination between that announcement and the White House order is not.

The proposed settlement is a separate mechanism for resolving claims. It would create a long-term compensation program for qualifying allegations involving non-Hodgkin lymphoma following exposure before February 17, 2026. Monsanto says payments into the program could continue for up to 21 years. Settlement terms and eligibility rules, not the executive order, would determine who is covered and what claims are released.

The Missouri court granted preliminary approval on March 4. A final-approval hearing took place September 14. As of this article’s October 16 research cutoff, the court-authorized settlement administrator’s website still described final approval as a future requirement, and we could not verify a final-approval order. The proposal should therefore not be presented as an approved and fully operating payout program.

The administrator’s official settlement documents contain the notice, settlement agreement, covered-product list, and court orders. People potentially affected should use those records or obtain independent legal advice rather than assume a social-media post accurately describes their rights or deadlines.

Bayer has explicitly described the class settlement and the Supreme Court litigation as complementary ways to contain Roundup litigation exposure. That is the company’s stated strategy, not evidence that an individual claimant’s allegations are false.

Why Did the Government Call Glyphosate a National-Security Issue?

The executive order’s national-security explanation rests on a connection between agriculture and strategic materials.

Glyphosate is widely used in U.S. corn, soybean, cotton, and other production systems. Its weed-control role has become integrated into farm equipment, seed systems, labor costs, and some reduced-tillage farming practices. Rapidly losing access could require growers to change weed-management practices, absorb additional costs, or alter crop management. The size of those effects would depend on the crop, region, available substitutes, prices, and adaptation time.

Elemental phosphorus serves both glyphosate manufacturing and other industrial applications. The administration argues that domestic supply concentration creates a vulnerability affecting military inputs and agricultural production at once.

That makes the supply-chain concern intelligible without accepting every assertion about its severity. There are still unanswered economic questions:

• Which domestic facilities would receive binding priority or allocation instructions?
• How much glyphosate production, if any, would increase relative to imports?
• What costs would manufacturers, farmers, or taxpayers actually bear?
• Would government support affect the availability or adoption of alternative weed-management practices?

A national-security designation is a policy decision, not a toxicological clearance. It says the government considers continuity of supply important. It does not demonstrate that exposure is harmless.

Does Glyphosate Cause Cancer? What the Research Actually Shows

The scientific evidence is more complex than either a universal declaration of safety or a claim that every Roundup exposure causes cancer.

The most disputed human-health endpoint is non-Hodgkin lymphoma, a group of blood cancers. Researchers have studied occupational pesticide applicators, retrospective exposure reports, laboratory mechanisms, and animal experiments. These forms of evidence answer different questions and have different limitations.

Why IARC and EPA have reached different conclusions

In 2015, the World Health Organization’s International Agency for Research on Cancer (IARC) classified glyphosate as probably carcinogenic to humans, Group 2A. IARC cited limited evidence in humans, sufficient evidence in experimental animals, and strong evidence of genotoxicity.

EPA’s earlier 2017 human-health assessment reached a different conclusion, finding glyphosate not likely to be carcinogenic to humans under the conditions it assessed. EPA considered evidence in the context of registered uses and expected exposures, whereas IARC’s classification assesses whether a substance can cause cancer under some circumstances.

These methodological differences matter, but they do not make every disagreement disappear. Study selection, exposure characterization, biological mechanisms, and interpretation of inconsistent findings remain substantive questions.

EPA’s 2020 interim registration-review decision was later challenged. The Ninth Circuit vacated its human-health portion in 2022, and EPA withdrew the entire interim decision in September 2022. EPA said the withdrawal did not, by itself, reverse its underlying scientific assessment. It is inaccurate to describe that withdrawn interim decision as an unchallenged final 2026 determination.

What the human and animal studies show

In the 2026 review’s detailed analysis, the ever-exposure estimate had a 95% confidence interval of approximately 0.98–1.27, which includes no association. The highest-exposure estimate was approximately 1.38, with a confidence interval near the statistical threshold. These findings support taking higher-exposure associations seriously without claiming that the literature has settled every causal question.

A further distinction is frequently missed: glyphosate is an active ingredient, while Roundup and other glyphosate-based herbicides are formulated products. Formulations may include surfactants and other ingredients that influence exposure and toxicity. Different historical products should not be treated as chemically identical. The 2025 animal study, for example, explicitly examined both pure glyphosate and named commercial formulations.

What about the retracted safety review?

A widely cited 2000 review favorable to glyphosate’s safety was retracted in late 2025 following journal concerns about authorship, sponsor contributions, conflicts of interest, and omitted evidence. Those are material scientific-integrity concerns, not an incidental controversy.

But a retracted review does not automatically invalidate every study discussed in it. EPA states that it does not rely directly on review articles for its pesticide risk determinations and that the retraction does not change its assessment. That is EPA’s explanation, which readers can examine alongside the retraction notice and underlying research.

The defensible position is straightforward: the carcinogenicity question deserves careful, transparent review, especially for higher occupational exposures and specific formulations. Neither a jury verdict nor an EPA label approval should be mistaken for the final scientific word.

Where Does RFK Jr. Stand on Glyphosate Now?

Robert F. Kennedy Jr.’s role is part of the story, but it should be described from his actual statements rather than inferred from political labels.

Kennedy was a member of Dewayne Johnson’s legal team in the landmark 2018 Roundup trial. The jury initially awarded Johnson roughly $289.2 million. That was not the final damages award: the California appellate court’s modified 2020 opinion reduced compensatory and punitive damages to approximately $10.25 million each, or about $20.51 million in total, before costs.

The jury’s determination concerned Johnson’s case, with its particular evidence and burden of proof. It did not establish the population-wide probability of cancer from every glyphosate exposure.

In February 2026, Kennedy publicly supported Trump’s production order. In the same statement, he described pesticides and herbicides as toxic by design, criticized dependence on agricultural chemicals, and argued that abruptly removing those inputs would destabilize farming and food prices. His support was framed around protecting domestic supply while changing the agricultural system over time.

That is a genuine policy tension: supporting continued production of a chemical while acknowledging concerns about its use. It is not evidence that Kennedy declared glyphosate harmless, and it does not by itself establish why he chose that position.

On September 22, EPA and HHS announced a memorandum of understanding to expand scientific cooperation on glyphosate. The agencies identified formulations and surfactants, occupational epidemiology, biomonitoring, dietary exposure, and potential research gaps as areas of work. HHS institutions, including the National Institute of Environmental Health Sciences and National Cancer Institute, are expected to contribute expertise.

EPA retains final pesticide-registration authority. The agreement gives HHS a scientific role; it does not transfer regulatory control to Kennedy’s department or predetermine the outcome.

What Happens Next?

Four developments will determine whether the federal policy produces consequences beyond its current legal language:

1. USDA implementation: Whether identifiable priority or allocation orders are issued, to whom, and with what measured effects on domestic production.
2. Court application: Whether manufacturers attempt to use the glyphosate executive order’s Section 707 language in particular injury lawsuits, and how courts address that defense.
3. Settlement approval and claims: Whether the Missouri court finally approves the proposed nationwide agreement, including any changes affecting covered class members and releases.
4. Scientific reassessment: Whether EPA’s forthcoming review changes the agency’s conclusions, registrations, exposure restrictions, or labeling requirements.

There is one near-term public deadline. EPA extended the comment period on its open-literature search to November 23, 2026, under docket EPA-HQ-OPP-2009-0361. The September EPA-HHS announcement anticipates completion of the updated human-health risk assessment in early 2027. These are announced schedules, not completed findings.

The Bottom Line

The United States took three materially different steps in 2026: it treated glyphosate production as a strategic supply concern, the Supreme Court restricted a major category of cancer-warning lawsuits, and federal health agencies began a renewed scientific review. A proposed class settlement adds a fourth, separate path for resolving claims.

None of these actions, alone or together, establishes blanket immunity for every Roundup manufacturer or proves that glyphosate is harmless. The real story is where supply-chain authority, product-liability law, and scientific oversight intersect, and where their limits have yet to be tested.

References and Further Reading

Federal Law and Government Policy

• Executive Order 14387: Promoting the National Defense by Ensuring an Adequate Supply of Elemental Phosphorus and Glyphosate-Based Herbicides, White House, February 18, 2026. The controlling text for delegated USDA powers, the corporate-viability clause, and the reference to Section 707 immunity.
• 50 U.S.C. § 4557: Defense Production Act liability provision, U.S. Code. Establishes the statutory protection for conduct resulting from compliance with qualifying federal directives.
• 7 C.F.R. Part 789: Agriculture Priorities and Allocations System, federal regulation. Explains the mechanisms for USDA priority and allocation actions.
• EPA and HHS Announce New Scientific Partnership to Strengthen Glyphosate Review, EPA, September 22, 2026. Defines the scope of the interagency scientific review and confirms EPA’s continued decision-making authority.
• Glyphosate Open Literature Search: Extension of Comment Period, Federal Register, September 28, 2026. Verifies the November 23 deadline and regulatory docket.

Court Decisions and Settlement Documents

• Hercules Inc. v. United States, 24 F.3d 188, Federal Circuit, 1994. Historical interpretation of Section 707 in Agent Orange manufacturing litigation.
• United States v. Vertac Chemical Corp., 46 F.3d 803, Eighth Circuit, 1995. Considers the boundary between production directives and environmental liability.
• August 19, 2026, California pipeline litigation order, U.S. District Court, Central District of California. A contemporary application of Section 707 that expressly discusses the Agent Orange precedents.
• Monsanto Co. v. Durnell, No. 24-1068, U.S. Supreme Court, June 25, 2026. Majority opinion, concurrence, and dissent concerning FIFRA labeling preemption.
• Hoge v. Monsanto Company, Document 133, U.S. District Court, District of Idaho, October 1, 2026. Demonstrates the case-specific distinction between dismissed labeling claims and surviving negligence and design-defect theories.
• Johnson v. Monsanto Co., modified appellate opinion, California Court of Appeal, August 18, 2020. Documents the verdict, procedural history, and reduced damages in the 2018 case.
• Weed Killer Class Settlement: Official Website and Program Documents, court-authorized settlement administrator. Primary public information on the proposed settlement, notices, eligibility, and court filings. Approval status is subject to change.

Scientific Assessments and Studies

• IARC Monograph on Glyphosate, International Agency for Research on Cancer, 2015. Explains the Group 2A classification and its evidentiary basis.
• EPA: Glyphosate and Withdrawal of the 2020 Interim Decision, U.S. EPA. Documents the agency’s existing position, review history, and effect of the 2022 litigation.
• Glyphosate Use and Cancer Incidence in the Agricultural Health Study, Andreotti et al., Journal of the National Cancer Institute, 2018. Large prospective occupational cohort.
• Exposure to Glyphosate-Based Herbicides and Risk for Non-Hodgkin Lymphoma, Zhang et al., Mutation Research, 2019. Meta-analysis emphasizing high cumulative exposure.
• Carcinogenic Effects of Long-Term Exposure to Glyphosate and Glyphosate-Based Herbicides in Rats, Panzacchi et al., Environmental Health, 2025. Animal evidence involving the active ingredient and separate formulations.
• A Systematic Review and Meta-Analysis of Glyphosate-Based Herbicide Exposure and Risk of Non-Hodgkin Lymphoma, Gagnier and O’Connor, International Journal of Environmental Research and Public Health, 2026. Updated human evidence synthesis; exposure definitions and statistical uncertainty are important to interpretation.
• Retraction Notice for the Williams, Kroes, and Munro Glyphosate Review, Regulatory Toxicology and Pharmacology, 2025. Documents the formal retraction and supports scrutiny of research provenance.

Company and Public-Official Statements

• Monsanto Announces Proposed Roundup Class Settlement, Bayer, February 17, 2026. Establishes the company’s announced financial terms and litigation strategy, not independent proof of the settlement’s fairness.
• Bayer’s 2026 Second-Quarter Media Update, Bayer, 2026. Confirms the consolidation of U.S. glyphosate operations into Ruveon.
• Secretary Kennedy’s Statement on the Executive Order, public statement, February 2026. Direct evidence of Kennedy’s stated rationale for supporting domestic supply while criticizing chemical dependence.

Editorial currency note: Research cutoff October 16, 2026. Litigation, settlement approval, USDA implementation, and EPA’s registration review are subject to change. The scientific discussion distinguishes glyphosate as an active ingredient from individual commercial formulations. This article provides public-interest legal and scientific analysis, not advice about an individual’s medical diagnosis or legal claim.